ArleneO.Siefker-RadtkeMD

Oncology • Houston, TX

Genitourinary Oncology, Hematologic Oncology

Associate Professor of Genitourinary Medical Oncology

Join to view full profile

Dr. Siefker-Radtke is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Siefker-Radtke's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1999 - 2002
Tufts Medical CenterResidency, Internal Medicine, 1996 - 1999
Johns Hopkins University School of MedicineClass of 1996

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2001 - 2026
OK State Medical License 2020 - 2021

Clinical Trials

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment Start of enrollment: 2000 Dec 01
Terminated
Phase 2
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone Start of enrollment: 2003 Mar 20
Completed
Phase 1
Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Start of enrollment: 2003 Apr 23
Active, not recruiting
Phase 2
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer Start of enrollment: 2004 Feb 01
Terminated
Phase 2
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Start of enrollment: 2006 Sep 28
Active, not recruiting
Phase 1
Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer Start of enrollment: 2007 Jun 01
Completed
Phase 2
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Start of enrollment: 2008 Jun 10
Completed
Phase 2
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors Start of enrollment: 2012 Jan 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).
Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, Arjun Balar, Daniel Castellano
Urologic Oncology. 2024-10-29
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analys...
Peter H O'Donnell, Yohann Loriot, Tibor Csoszi, Nobuaki Matsubara, Sang Joon Shin
Cancer. 2024-10-28
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer.
Matthew T Campbell, Amishi Y Shah, Pavlos Msaouel, Nizar M Tannir, Arlene O Siefker-Radtke
Cancer Research Communications. 2024-09-01

Lectures

Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.
2019 ASCO Annual Meeting - 6/1/2019
FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary anal...
2019 ASCO Annual Meeting - 6/1/2019
Tailoring of Chemotherapy to Fit Patients With Metastatic Urothelial Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelia...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Press Mentions

NCCN Clinical Practice Guidelines in Oncology: 2023 UpdatesMay 19th, 2023
Can Frequent UTIs Be a Sign of Bladder Cancer?March 9th, 2023
Neoadjuvant Chemotherapy Shows “Clear Benefit” in Upper Tract Urothelial CarcinomaJanuary 26th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member